-
公开(公告)号：AU2010222693B2
公开(公告)日：2014-12-04
申请号：AU2010222693
申请日：2010-03-10
Applicant: UCB PHARMA SA
Inventor： GOZZARD NEIL , LAWSON ALASTAIR DAVID GRIFFITHS , LIGHTWOOD DANIEL JOHN , PALFRAMAN ROGER THOMAS , SMITH BRYAN JOHN , TYSON KERRY LOUISE
IPC: C07K16/24 , A61K39/395 , A61P11/06 , C07K16/46 , C12N15/13
Abstract: Antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：EA019636B1
公开(公告)日：2014-05-30
申请号：EA200970879
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: Изобретениеотноситсяк связывающимбелкам, включающимантитела, производныеантители фрагментыантител, которыеспецифическисвязываютсяс белком CD154 (CD40L). Такжеданноеизобретениеотноситсяк химерному, гуманизированномуилиполностьючеловеческомуантителу, производномуантителаи фрагментуантитела, которыеспецифическисвязываютсяс эпитопом, скоторымспецифическисвязываетсягуманизированныйфрагмент Fab, содержащийпоследовательностьвариабельнойобластитяжелойцепи SEQ ID NO: 1 исодержащийпоследовательностьвариабельнойобластилегкойцепи SEQ ID NO: 2. CD154-связывающиебелкиподанномуизобретениюмогутпроявлятьпониженнуюэффекторнуюфункциюпосравнениюсовторыманти-CD154-антителом. CD154-связывающиебелкиподанномуизобретениюмогутбытьпригоднымидлядиагностическихи терапевтическихспособов, напримерприлечениии профилактикезаболеваний, втомчислетаковых, которыевключаютнежелательныеиммунныереакции, опосредуемыевзаимодействиями CD154-CD40.
-
公开(公告)号：SG196697A1
公开(公告)日：2014-02-13
申请号：SG2012055786
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Abstract: - 126 - Abstract BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODYDERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 ANDUSES THEREOF This invention provides binding proteins, includingantibodies, antibody derivatives and antibody fragments, thatspecifically bind a CD 154 (CD4OL) protein. This invention alsoprovides a chimeric, humanized or fully human antibody, antibodyderivative or antibody fragment that specifically binds to an epitopeto which a humanized Fab fragment comprising a variable heavy chainsequence according to SEQ ID NO: 1 and comprising a variable lightchain sequence according to SEQ ID NO: 2 specifically binds. CD154binding proteins of this invention may elicit reduced effectorfunction relative to a second anti-CD154 antibody. CD154 bindingproteins of this invention are useful in diagnostic and therapeuticmethods, such as in the treatment and prevention of diseasesincluding those that involve undesirable immune responses that aremediated by CD154-CD40 interactions. Fig. 19
-
公开(公告)号：CA2872326A1
公开(公告)日：2014-02-06
申请号：CA2872326
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
-
公开(公告)号：NZ580245A
公开(公告)日：2012-01-12
申请号：NZ58024508
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: An anti-CD154 antibody that comprises the heavy chain CDR1, CDR2 and CDR3 sequence SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 respectively and the light chain CDR1, CDR2 and CDR3 sequences SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 respectively. Also disclosed are methods of the production of the antibody and uses thereof for treating rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, inflammatory bowel disease, Crohn's disease, psoriasis, scleroderma and multiple sclerosis.
-
Patent Agency Ranking
公开(公告)号：CA2754539A1
公开(公告)日：2010-09-16
申请号：CA2754539
申请日：2010-03-10
Applicant: UCB PHARMA SA
Inventor： GOZZARD NEIL , LAWSON ALASTAIR DAVID GRIFFITHS , LIGHTWOOD DANIEL JOHN , PALFRAMAN ROGER THOMAS , SMITH BRYAN JOHN , TYSON KERRY LOUISE
IPC: C07K16/24 , A61K39/395 , A61P11/06 , C07K16/46 , C12N15/13
Abstract: Antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：ECSP099683A
公开(公告)日：2009-12-28
申请号：ECSP099683
申请日：2009-10-08
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： POPPLEWELL ANDREW GEORGE , BROWN DEREK THOMAS , ADAMS RALPH , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Abstract: Esta invención proporciona proteínas de unión, que incluyen anticuerpos, derivados de anticuerpo, y fragmentos de anticuerpo, que específicamente se unen a la proteína CD154 (CD40L). Esta invención también proporciona un anticuerpo quimérico, humanizado o completamente humano, derivado de anticuerpo o fragmento de anticuerpo que específicamente se une a un epítopo al cual se une un fragmento Fab humanizado que comprende una secuencia de cadena pesada variable de acuerdo con SEC ID NO: 1 y comprende una secuencia de cadena ligera variable de acuerdo con SEC ID NO: 2. Las proteínas de unión CD154 de esta invención pueden producir una función efectora reducida con relación a un segundo anticuerpo anti-CD154. Las proteínas de unión CD154 de la invención son útiles en métodos de diagnóstico y terapéuticos, tales como en el tratamiento y prevención de enfermedades que incluyen las que involucran respuestas inmunitarias indeseables que están mediadas por las interacciones de CD154-CD40
-
公开(公告)号：EA032222B1
公开(公告)日：2019-04-30
申请号：EA201101303
申请日：2010-03-10
Applicant: UCB PHARMA SA
Inventor： GOZZARD NEIL , LAWSON ALASTAIR DAVID GRIFFITHS , LIGHTWOOD DANIEL JOHN , PALFRAMAN ROGER THOMAS , SMITH BRYAN JOHN , TYSON KERRY LOUISE
IPC: C07K16/24 , A61K39/395 , A61P11/06 , C07K16/46 , C12N15/13
Abstract: Визобретенииописанымолекулыантител, обладающиеспецифичностьюв отношенииантигенныхдетерминант IL-13 человека, терапевтическиеприменениямолекулантители способыполученияуказанныхмолекулантител.
-
公开(公告)号：AU2012307157B2
公开(公告)日：2017-08-03
申请号：AU2012307157
申请日：2012-09-10
Applicant: UCB PHARMA SA
Inventor： HUMPHREYS DAVID PAUL , LIGHTWOOD DANIEL JOHN , TYSON KERRY LOUISE , KNIGHT DAVID EDWARD ORMONDE , HERVE KARINE JEANNINE MADELEINE , COMPSON JOANNE ELIZABETH , PAGE MATTHEW JON TIMOTHY , PAYNE ANDREW CHARLES , FISHER NICOLA LOUISE , MACKENZIE BRENDON , COX MATTHEW
Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of
-
公开(公告)号：PE00022015A1
公开(公告)日：2015-01-28
申请号：PE0019872014
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
CPC classification number: C07K16/283 , A61K39/3955 , A61K47/60 , A61K47/643 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/5047 , G01N33/564 , G01N33/6854 , G01N33/6857 , G01N33/6893 , G01N2333/70535 , G01N2500/02 , G01N2500/10 , G01N2800/104 , G01N2800/24 , G01N2800/28
Abstract: SE REFIERE A UN ANTICUERPO O FRAGMENTO DE UNION DEL MISMO ANTI-FCRN QUE COMPRENDE: UNA CADENA PESADA QUE TIENE UNA REGION VARIABLE QUE COMPRENDE TRES CDR SELECCIONADAS INDEPENDIENTEMENTE DE SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 ; Y UNA CADENA LIGERA QUE TIENE UNA REGION VARIABLE QUE COMPRENDE TRES CDR SELECCIONADAS INDEPENDIENTEMENTE DE SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.02 seconds)
